Last reviewed · How we verify
standard quadruple therapy
standard quadruple therapy is a Antimicrobial combination therapy Small molecule drug developed by Les Laboratoires des Médicaments Stériles. It is currently FDA-approved for Tuberculosis (drug-susceptible), Helicobacter pylori infection (refractory cases). Also known as: Qs-14.
Standard quadruple therapy combines four antimicrobial agents to treat infections, typically used in tuberculosis or Helicobacter pylori eradication.
Standard quadruple therapy is a treatment modality that involves the use of small molecule drugs. It has been studied in various clinical trials for conditions such as Tuberculosis, Multidrug Resistant Tuberculosis, Helicobacter Pylori, and Multiple Myeloma.
At a glance
| Generic name | standard quadruple therapy |
|---|---|
| Also known as | Qs-14 |
| Sponsor | Les Laboratoires des Médicaments Stériles |
| Drug class | Antimicrobial combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Quadruple therapy refers to a fixed combination of four drugs designed to work synergistically against a pathogen. In tuberculosis, this typically includes isoniazid, rifampicin, pyrazinamide, and ethambutol. In H. pylori infection, it may include a proton pump inhibitor, bismuth subsalicylate, and two antibiotics. The multi-drug approach reduces resistance development and improves treatment efficacy.
Approved indications
- Tuberculosis (drug-susceptible)
- Helicobacter pylori infection (refractory cases)
Common side effects
- Gastrointestinal disturbance
- Hepatotoxicity
- Peripheral neuropathy
- Hyperuricemia
- Optic neuritis
Key clinical trials
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial (PHASE3)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Isa-VRD in TIE HRMM (PHASE4)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard quadruple therapy CI brief — competitive landscape report
- standard quadruple therapy updates RSS · CI watch RSS
- Les Laboratoires des Médicaments Stériles portfolio CI
Frequently asked questions about standard quadruple therapy
What is standard quadruple therapy?
How does standard quadruple therapy work?
What is standard quadruple therapy used for?
Who makes standard quadruple therapy?
Is standard quadruple therapy also known as anything else?
What drug class is standard quadruple therapy in?
What development phase is standard quadruple therapy in?
What are the side effects of standard quadruple therapy?
Related
- Drug class: All Antimicrobial combination therapy drugs
- Manufacturer: Les Laboratoires des Médicaments Stériles — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Tuberculosis (drug-susceptible)
- Indication: Drugs for Helicobacter pylori infection (refractory cases)
- Also known as: Qs-14
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing